- November 8 at 3:30 p.m. MST at the 25th Annual Credit Suisse Healthcare Conference
- November 16 at 1:20 p.m. GMT at the Jefferies 2016 London Healthcare Conference
- November 29 at 12:30 p.m. EST at the 28th Annual Piper Jaffray Healthcare Conference
Axovant Sciences (AXON) stock slid on Thursday after an Alzheimer's drug by Danish pharmaceutical company Lundbeck failed a phase III study.
Analysts believe that the biotech company could fetch up to $6 billion in a sale since its compound will be the first in a new class of anti-psychotic drugs.